Investors & Media

Press Releases

Date Title View
Toggle Summary SAGE Therapeutics to Present at the Canaccord Genuity 35th Annual Growth Conference
CAMBRIDGE, Mass. , Aug. 5, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced that Jeff Jonas , M.D., chief executive officer of SAGE,
View HTML
Toggle Summary SAGE Therapeutics Announces Positive Top-Line Data in Exploratory Trial of SAGE-547 in Postpartum Depression
Marked Improvement Demonstrated in HAM-D Scores in Patients with PPD Enrolled in Open-Label Trial Plan to Initiate Placebo-Controlled Trial of SAGE-547 by Year End and Advance Novel Product Candidates for Potential Development CAMBRIDGE, Mass. , June 9, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics
View HTML
Toggle Summary SAGE Therapeutics to Participate in the Goldman Sachs 36th Annual Global Healthcare Conference
CAMBRIDGE, Mass. , June 3, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced that Jeff Jonas , M.D., chief executive officer of SAGE
View HTML
Toggle Summary SAGE Therapeutics Announces SAGE-547 Progress and First Quarter 2015 Financial Results
SAGE-547 Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in SRSE Conference Call Scheduled Today at 8:30 a.m. ET CAMBRIDGE, Mass. , May 14, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel
View HTML
Toggle Summary SAGE Therapeutics Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in Super-Refractory Status Epilepticus
SAGE-547 Demonstrates Favorable Tolerability Pharmacodynamic Activity Corroborated by Continuous EEG Findings Phase 3 STATUS Trial Expected to Initiate by Mid-2015 Conference Call Scheduled Today at 8:30 a.m. ET CAMBRIDGE, Mass. , May 14, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE)
View HTML
Toggle Summary SAGE Therapeutics to Present at UBS Global Healthcare Conference
CAMBRIDGE, Mass. , May 12, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceuticals company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced that Jeff Jonas , M.D., chief executive officer of
View HTML
Toggle Summary SAGE Therapeutics to Report First Quarter 2015 Financial Results on Thursday, May 14
CAMBRIDGE, Mass. , May 7, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced that the company will host a conference call and live
View HTML
Toggle Summary SAGE Therapeutics Announces Closing of $138 Million Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares
CAMBRIDGE, Mass. , April 21, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 342,857 shares at
View HTML
Toggle Summary SAGE Therapeutics Announces First Patient Treated Under Phase 3 Expanded Access Protocol to Evaluate SAGE-547 in Patients With Super-Refractory Status Epilepticus
Phase 3 STATUS Trial - Randomized, Double-Blind, Placebo-Controlled Clinical Trial of SAGE-547 for the Treatment of Patients With SRSE - Expected to Initiate by Mid-2015
View HTML
Toggle Summary SAGE Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass. , April 14, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of
View HTML